17 Aug 2017
N+1 Singer - Oxford BioMedica - Interim results; CTL019 approval anticipated by early October
Oxford BioMedica’s interim results highlight the continued step up in bioprocessing and commercial development income. A new agreement with Novartis for the commercial and clinical supply of lentiviral vectors was recently established following the FDA advisory committee unanimously recommending CTL019 for approval in acute lymphoblastic leukaemia (ALL). Approval is anticipated by early October 2017. Novartis also announced encouraging Phase II results in a trial evaluating CTL019 in diffuse lar ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - Interim results; CTL019 approval anticipated by early October
Oxford BioMedica plc (OXB:LON) | 216 5.4 1.2% | Mkt Cap: 215.8m
- Published:
17 Aug 2017 -
Author:
Sheena Berry -
Pages:
4
Oxford BioMedica’s interim results highlight the continued step up in bioprocessing and commercial development income. A new agreement with Novartis for the commercial and clinical supply of lentiviral vectors was recently established following the FDA advisory committee unanimously recommending CTL019 for approval in acute lymphoblastic leukaemia (ALL). Approval is anticipated by early October 2017. Novartis also announced encouraging Phase II results in a trial evaluating CTL019 in diffuse lar ....